Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC
Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.
No comments:
Post a Comment